Incyte to present initial data on cancer therapies at ESMO Congress

WILMINGTON, Del. - Incyte (NASDAQ:INCY), a $13.7 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, will present early-phase clinical data for two investigational cancer therapies at the European Society of Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21 in Berlin.

The biopharmaceutical company, which has demonstrated impressive revenue growth of 17% over the last twelve months, will showcase initial Phase 1 data for INCA33890, a TGFΒR2×PD-1-directed bispecific antibody being studied in patients with advanced or metastatic solid tumors. This presentation will take place during a mini oral session focused on investigational immunotherapy on October 17.

Additionally, Incyte will deliver an oral presentation featuring preliminary results from a Phase 1 study of INCB161734, described as a novel, selective and orally bioavailable inhibitor targeting G12D-mutated KRAS in patients with advanced or metastatic solid tumors. This presentation is scheduled for October 19.

The company will also present data on retifanlimab, an anti-PD-1 monoclonal antibody, alone or in combination with anti-LAG3 with or without anti-TIM3 monoclonal antibodies in previously untreated, recurrent and/or metastatic PD-L1+ head and neck squamous cell carcinoma.

"These data underscore the importance of establishing treatment options for advanced solid tumors," said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte, in a press release statement.

All accepted abstracts for the ESMO Congress 2025 will be published online via the ESMO website on October 13 and in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Incyte, headquartered in Wilmington, Delaware, focuses on discovering, developing and commercializing proprietary therapeutics for patients with unmet medical needs, with operations across North America, Europe and Asia. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 2.04. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including Incyte.

In other recent news, Incyte has announced a significant leadership change with the appointment of Bill Meury as the new President and CEO. Meury takes over from Hervé Hoppenot, who is retiring after 11 years at the helm but will remain as an advisor and board member through the end of the year to assist with the transition. This leadership shift has been well-received, with Citi reiterating its buy rating and maintaining a price target of $88, while William Blair continues to rate the stock as Market Perform. In addition to the leadership changes, UBS has raised its price target for Incyte to $62 from $61, reflecting a slightly improved sales outlook for Niktimvo and an upward revision in the firm’s 2026 earnings per share estimate to $6.36. These developments indicate a positive outlook for Incyte, with analysts showing confidence in the company’s future performance under new leadership.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.